Long-Lived Patients With Primary Myelofibrosis: What Predicts a 20+ Year Survival?
A retrospective study identified prognostic factors for long survival — 20+ years — in patients with primary myelofibrosis.
Hematologic Cancers
Multiple Myeloma Treatment Regimens
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
Uncertainty Common in Primary Family Caregivers of Patients With Multiple Myeloma
Researchers find trends among physical and emotional challenges associated with being the primary family caregiver of a patient with multiple myeloma.
Cancer Clinic Specializes in Assessments, Treatment of the Nonfrail Elderly
Oncologist Ashley Rosko, MD, has a unique perspective on patient age: Biological age is more important than chronological age. Dr Rosko is founder and director of the Cancer and Aging Resiliency (CARE) Clinic, a multidisciplinary clinic designed to address the needs of older adults with cancer. The clinic is located in The James Cancer Hospital…
Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
A retrospective study using a cohort of the ALiCCS Study sought to determine hospitalization risks among survivors of leukemia during childhood 20 years after diagnosis.
FDA Approves Tagraxofusp, First Approved Treatment for a Rare, Aggressive Hematologic Cancer
FDA grants approval to tagraxofusp-erzs (Elzonris), a first treatment for blastic plasmacytoid dentritic cell neoplasm and the first therapy to target CD123.
Mini-Pools of IVIG Just as Effective as Standard IVIG in Pediatric Immune Thrombocytopenia
Intravenous immunoglobulin G with plasma from fewer blood donations provides sufficient therapeutic effect for pediatric patients with ITP.
Apixaban Significantly Lowers Risk of Venous Thromboembolism in High-Risk Patients
A clinical trial demonstrates that apixaban effectively decreases risk of VTE in patients with cancer; however, risk of major bleeding episodes may be higher.
Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
FDA Grants Approval to New Treatment for Acute Myeloid Leukemia
Randomized clinical trial showed significant improvement in overall survival with glasdegib.
Next post in Leukemia
